Blood News and Research

RSS
Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Vascular surgeries provide relief from two debilitating conditions

Vascular surgeries provide relief from two debilitating conditions

Strategies needed to optimize communications between police and ED workers

Strategies needed to optimize communications between police and ED workers

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Researchers identify 763 proteins in human aqueous humor that nourish the cornea and the lens

Researchers identify 763 proteins in human aqueous humor that nourish the cornea and the lens

PEPRR intervention successfully reduces stress of cancer caregivers

PEPRR intervention successfully reduces stress of cancer caregivers

Novel biosensor chip measures pH, temperature, drugs and metabolism-related molecules

Novel biosensor chip measures pH, temperature, drugs and metabolism-related molecules

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.